Publications by authors named "Madlen Witt"

The field of ocular diseases, specifically retinal diseases is a successful target area for protein drugs with various marketed products. Besides the intraocular treatment of the retina, the topical treatment of corneal or conjunctival diseases is a promising approach. Topical ocular protein formulations face the challenges of poor penetration and potentially low stability.

View Article and Find Full Text PDF

High concentration protein formulations for subcutaneous injection represent a substantial number of development projects in the pharmaceutical industry. Such concentrated aqueous protein solutions face some specific challenges such as increased viscosity and aggregation propensity. Protein powder suspensions in non-aqueous vehicles could be an alternative providing lower viscosity than the respective aqueous solution.

View Article and Find Full Text PDF

Pharmaceutical formulations utilizing protein drugs as powders can be used as drug delivery systems in various ways. Besides powders for inhalation, another promising approach is their use as suspensions in non-aqueous liquids for subcutaneous administration providing high protein stability and good injectability. In this study protein powder suspensions were prepared using a swing-mill.

View Article and Find Full Text PDF

Formulating biopharmaceuticals is a challenging task due to their complex and sensitive nature. Protein drugs are typically marketed either as an aqueous solution or as a lyophilizate. Usually aqueous solutions are preferred as neither drying nor reconstitution are required.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores how semifluorinated alkanes (SFAs), specifically perfluorohexyloctane (F6H8), can be used to deliver vascular endothelial growth factor (VEGF) Trap to inhibit corneal neovascularization in mice.
  • Treatment with Trap/F6H8 showed comparable effectiveness to the standard aqueous VEGF Trap in reducing blood and lymph vessel formation in the cornea after two weeks.
  • Results suggest that F6H8 might be a promising carrier for anti-angiogenic therapies in the eye, potentially leading to new treatments for ocular conditions involving abnormal blood vessel growth.
View Article and Find Full Text PDF